During Wednesday's Lightning Round segment of Mad Money one caller asked Jim Cramer about Amarin Corp. (AMRN) : "This is speculative and should only be bought as a spec," he replied about the biopharma company that develops and markets medicines for cardiovascular disease.
More from Investing
The shares have been correcting lower since early May.
The elevator maker's charts are pushing the right buttons.
Why we ever allowed Chinese businesses to raise capital, our capital, on our shores, is beyond me.